% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • redsavina2001 redsavina2001 Oct 13, 2012 3:18 PM Flag


    Dr. Steven Rowe the first clinician to inject VX-770 for research in this country says:

    ".....Dr. Steven Rowe of the University of Alabama, Birmingham and also an investigator in the VX-809/Kalydeco study, had a similar view:

    "It's exciting to see the combination treatment come to fruition. It's a phase II design and we've been fooled before but this looks pretty convincing."

    Rowe on what a 6% improvement in lung function means to a CF patient:

    "FEV1 is a speedometer for CF patients. It's what they check every time they come to clinic and so, even small changes mean a fair amount to patients. These results compare favorably to many other drugs that have been approved and widely used for CF, so I think people would be excited about it."

89.12+0.83(+0.94%)4:00 PMEDT